JPMORGAN CHASE & CO - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$411,737
-21.8%
47,710
-6.2%
0.00%
Q2 2023$526,442
-77.2%
50,864
-76.1%
0.00%
Q1 2023$2,306,000
+96023.4%
212,527
-0.6%
0.00%
Q4 2022$2,399
-99.9%
213,848
+6.9%
0.00%
Q3 2022$2,030,000
+8.0%
200,113
-3.5%
0.00%
Q2 2022$1,879,000
+13.5%
207,355
+19.7%
0.00%
Q1 2022$1,656,000
-27.0%
173,292
-15.5%
0.00%
Q4 2021$2,267,000
+31.3%
205,110
-12.1%
0.00%
Q3 2021$1,726,000
+235.1%
233,269
+558.1%
0.00%
Q2 2021$515,000
-12.3%
35,448
+23.3%
0.00%
Q1 2021$587,000
-9.4%
28,752
-21.3%
0.00%
Q4 2020$648,000
+151.2%
36,515
+113.0%
0.00%
Q3 2020$258,000
-20.9%
17,147
+10.4%
0.00%
Q2 2020$326,000
-10.9%
15,536
-1.9%
0.00%
Q1 2020$366,000
-1.6%
15,842
+10.2%
0.00%
Q4 2019$372,000
+10.4%
14,382
-17.0%
0.00%
Q3 2019$337,000
-77.2%
17,332
-81.3%
0.00%
Q2 2019$1,477,000
-67.4%
92,483
-53.7%
0.00%
-100.0%
Q1 2019$4,530,000
+27.2%
199,845
+43.6%
0.00%0.0%
Q4 2018$3,560,000
+815.2%
139,145
+1068.8%
0.00%
Q3 2018$389,000
+97.5%
11,905
+36.8%
0.00%
Q2 2018$197,000
-17.9%
8,703
-12.0%
0.00%
Q1 2018$240,000
-15.5%
9,892
-2.8%
0.00%
Q4 2017$284,000
-79.3%
10,181
-74.2%
0.00%
Q3 2017$1,369,000
-15.1%
39,494
-2.4%
0.00%
Q2 2017$1,612,000
-6.6%
40,474
-13.7%
0.00%
Q1 2017$1,726,000
-40.5%
46,887
-48.5%
0.00%
-100.0%
Q4 2016$2,901,000
+84.0%
90,976
+109.1%
0.00%
Q3 2016$1,577,000
+78750.0%
43,500
+39808.3%
0.00%
Q2 2016$2,0000.0%1090.0%0.00%
Q1 2016$2,000
-50.0%
109
-58.1%
0.00%
Q4 2015$4,0002600.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2022
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders